AstraZeneca PLC will keep making portfolio assets available for trials to evaluate their use in countering disease symptoms of COVID-19, with emphasis on preventing organ damage in severely affected patients, the UK pharma’s management said when presenting its first-quarter update that, despite the pandemic, showed strong revenue growth driven by good sales across all therapy areas.
Still, CEO Pascal Soriot said the fight against the SAR-CoV-2 virus was unlikely to alter the company’s long-term therapeutic focus,...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)